Apellis Pharmaceuticals Unusual Options Activity For August 11

Someone with a lot of money to spend has taken a bullish stance on Apellis Pharmaceuticals APLS.

And retail traders should know.

We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with APLS, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 10 options trades for Apellis Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 80% bullish and 20%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $43,200, and 9, calls, for a total amount of $449,577..

Get Started

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Get Started

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $50.0 for Apellis Pharmaceuticals over the last 3 months.

Volume & Open Interest Development

In terms of liquidity and interest, the mean open interest for Apellis Pharmaceuticals options trades today is 2394.5 with a total volume of 7,262.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Apellis Pharmaceuticals's big money trades within a strike price range of $25.0 to $50.0 over the last 30 days.

Apellis Pharmaceuticals Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Where Is Apellis Pharmaceuticals Standing Right Now?

• With a volume of 5,858,001, the price of APLS is up 14.24% at $30.86.
• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
• Next earnings are expected to be released in 87 days.

What The Experts Say On Apellis Pharmaceuticals:

• HC Wainwright & Co. downgraded its action to Buy with a price target of $82
• Citigroup has decided to maintain their Buy rating on Apellis Pharmaceuticals, which currently sits at a price target of $80.
• Baird has decided to maintain their Outperform rating on Apellis Pharmaceuticals, which currently sits at a price target of $70.
• Wedbush has decided to maintain their Neutral rating on Apellis Pharmaceuticals, which currently sits at a price target of $29.
• HC Wainwright & Co. downgraded its action to Buy with a price target of $82

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Apellis Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.